Mohit Bansal
Stock Analyst at Wells Fargo
(4.70)
# 783
Out of 5,074 analysts
829
Total ratings
57.2%
Success rate
9.8%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Reiterated: Buy | $250 → $310 | $253.84 | +22.12% | 57 | Oct 20, 2026 | |
| BMRN BioMarin Pharmaceutical | Rated: Buy | $80 | $56.63 | +41.27% | 29 | Oct 20, 2026 | |
| ABBV AbbVie | Reiterated: Buy | $300 | $285.19 | +5.19% | 44 | Oct 15, 2026 | |
| AMGN Amgen | Reiterated: Hold | $430 | $447.28 | -3.86% | 54 | Oct 15, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,330 | $1,306.69 | +1.78% | 70 | Oct 15, 2026 | |
| MRK Merck & Co. | Reiterated: Buy | $170 → $165 | $147.24 | +12.06% | 57 | Oct 15, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Hold | $750 | $819.09 | -8.43% | 70 | Oct 15, 2026 | |
| TVTX Travere Therapeutics | Reiterated: Buy | $80 | $52.43 | +52.58% | 24 | Oct 15, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | $70 | $29.05 | +140.96% | 13 | Oct 15, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $550 | $535.17 | +2.77% | 53 | Oct 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $25.84 | +16.10% | 1 | Oct 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $165 | $157.19 | +4.97% | 65 | Oct 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $65 → $60 | $63.00 | -4.76% | 46 | Oct 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $143.29 | +39.58% | 34 | Oct 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $28 | $30.42 | -7.96% | 54 | Oct 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $15.55 | +92.93% | 14 | Sep 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $140 | $89.67 | +56.13% | 14 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.7027 | +896.16% | 5 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 | $21.47 | +156.17% | 16 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $300 | $214.65 | +39.76% | 20 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $75 → $95 | $124.54 | -23.72% | 27 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $3.57 | +40.06% | 16 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $3.35 | +288.06% | 1 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $47 | $36.50 | n/a | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $95 | $58.36 | n/a | 1 | Jul 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 → $14 | $20.10 | n/a | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $3 | $0.000001 | n/a | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $52 | $0.8653 | n/a | 1 | Apr 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $33 | $36.12 | n/a | 2 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $27 | $1.05 | n/a | 6 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 → $75 | $5.60 | n/a | 2 | Jan 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $5 | $0.0001 | n/a | 5 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 → $65 | $37.19 | n/a | 5 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 → $8.5 | $2.44 | n/a | 4 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $5 | $0.025 | n/a | 2 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $21 | $17.15 | n/a | 1 | Jun 11, 2019 |
Biogen
Oct 20, 2026
Reiterated: Buy
Price Target: $250 → $310
Current: $253.84
Upside: +22.12%
BioMarin Pharmaceutical
Oct 20, 2026
Rated: Buy
Price Target: $80
Current: $56.63
Upside: +41.27%
AbbVie
Oct 15, 2026
Reiterated: Buy
Price Target: $300
Current: $285.19
Upside: +5.19%
Amgen
Oct 15, 2026
Reiterated: Hold
Price Target: $430
Current: $447.28
Upside: -3.86%
Eli Lilly and Company
Oct 15, 2026
Reiterated: Buy
Price Target: $1,330
Current: $1,306.69
Upside: +1.78%
Merck & Co.
Oct 15, 2026
Reiterated: Buy
Price Target: $170 → $165
Current: $147.24
Upside: +12.06%
Regeneron Pharmaceuticals
Oct 15, 2026
Reiterated: Hold
Price Target: $750
Current: $819.09
Upside: -8.43%
Travere Therapeutics
Oct 15, 2026
Reiterated: Buy
Price Target: $80
Current: $52.43
Upside: +52.58%
Vera Therapeutics
Oct 15, 2026
Reiterated: Buy
Price Target: $70
Current: $29.05
Upside: +140.96%
Vertex Pharmaceuticals
Oct 15, 2026
Reiterated: Buy
Price Target: $550
Current: $535.17
Upside: +2.77%
Oct 15, 2026
Reiterated: Buy
Price Target: $30
Current: $25.84
Upside: +16.10%
Oct 14, 2026
Rated: Buy
Price Target: $165
Current: $157.19
Upside: +4.97%
Oct 13, 2026
Rated: Hold
Price Target: $65 → $60
Current: $63.00
Upside: -4.76%
Oct 13, 2026
Reiterated: Buy
Price Target: $200
Current: $143.29
Upside: +39.58%
Oct 12, 2026
Reiterated: Hold
Price Target: $28
Current: $30.42
Upside: -7.96%
Sep 28, 2026
Reiterated: Buy
Price Target: $30
Current: $15.55
Upside: +92.93%
Sep 24, 2026
Reiterated: Buy
Price Target: $140
Current: $89.67
Upside: +56.13%
Aug 13, 2026
Reiterated: Buy
Price Target: $7
Current: $0.7027
Upside: +896.16%
Aug 12, 2026
Reiterated: Buy
Price Target: $55
Current: $21.47
Upside: +156.17%
Aug 10, 2026
Reiterated: Buy
Price Target: $300
Current: $214.65
Upside: +39.76%
Aug 7, 2026
Rated: Hold
Price Target: $75 → $95
Current: $124.54
Upside: -23.72%
May 5, 2026
Reiterated: Hold
Price Target: $5
Current: $3.57
Upside: +40.06%
Apr 1, 2026
Reiterated: Buy
Price Target: $13
Current: $3.35
Upside: +288.06%
Aug 12, 2025
Reiterated: Buy
Price Target: $47
Current: $36.50
Upside: n/a
Jul 2, 2021
Reiterated: Buy
Price Target: $95
Current: $58.36
Upside: n/a
Jun 29, 2021
Reiterated: Buy
Price Target: $30 → $14
Current: $20.10
Upside: n/a
Jun 4, 2021
Initiated Coverage: Buy
Price Target: $3
Current: $0.000001
Upside: n/a
Apr 5, 2021
Initiated Coverage: Buy
Price Target: $52
Current: $0.8653
Upside: n/a
Mar 24, 2021
Reiterated: Buy
Price Target: $20 → $33
Current: $36.12
Upside: n/a
Feb 25, 2021
Reiterated: Buy
Price Target: $25 → $27
Current: $1.05
Upside: n/a
Jan 20, 2021
Reiterated: Buy
Price Target: $36 → $75
Current: $5.60
Upside: n/a
Jan 5, 2021
Reiterated: Buy
Price Target: $10 → $5
Current: $0.0001
Upside: n/a
Dec 23, 2020
Reiterated: Buy
Price Target: $75 → $65
Current: $37.19
Upside: n/a
Sep 15, 2020
Reiterated: Hold
Price Target: $11 → $8.5
Current: $2.44
Upside: n/a
Apr 27, 2020
Reiterated: Buy
Price Target: $8 → $5
Current: $0.025
Upside: n/a
Jun 11, 2019
Initiated Coverage: Buy
Price Target: $21
Current: $17.15
Upside: n/a